The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)
Consulting or Advisory Role - Amgen (Inst); Arvinas; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CureVac; Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); Macrogenics; MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Pfizer
 
Whijae Roh
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Hinova Pharmaceuticals; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Xinmeng Jasmine Mu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Steven Yip
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; OncoHelix; Pfizer; Roche
 
Stefanie Zschaebitz
Honoraria - Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Eisai Germany; Ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Novartis; Pfizer (Inst)
Consulting or Advisory Role - Amgen; Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Gilead Sciences; Ipsen; Merck; MSD Oncology; Pfizer (Inst); Roche; Sanofi/Aventis (Inst)
Research Funding - Eisai (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; BMS GmbH & Co. KG; Ipsen; Janssen Oncology; Merck; Pfizer
 
Josep M. Piulats
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Clovis Oncology; Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Research Funding - BeiGene (Inst); BMSi (Inst); Janssen (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD (Inst); Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Glenn Liu
Employment - AIQ Solutions
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Consulting or Advisory Role - Janssen medical Affairs
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
 
Robert J. Jones
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; MSD; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche
Research Funding - Astellas Pharma; Bayer; Clovis Oncology; Exelixis; Roche
Travel, Accommodations, Expenses - Bayer; Janssen
 
Michelle Saul
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Arne Engelsberg
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jijumon Chelliserry
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Douglas Laird
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer